KRAS
A gene frequently mutated in cancers; long considered 'undruggable' until recent targeted therapies.
Coverage of KRAS is holding steady : 10 signals on the latest tracked day, down 47% from its three-week baseline of 19, across 3 domains (unchanged from a week ago). That makes it the #3 most-covered of the 289 concerns we track.
What’s changed
5 of the last 7 tracked days ran below the three-week baseline — a sustained cooling, not a one-day dip.
- Property-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor. · J Med Chem · 2026-08-13
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. · Sci Rep · 2026-08-13
- Akari’s PH1 Payload Shows Synergy With KRAS Inhibitor in Pancreatic Models - Stock Titan · KRAS Mutation Research (Google News) · 2026-08-13
- Brønsted-basic small molecules activate GTP hydrolysis in KRAS-Q61 mutants - Nature · KRAS Mutation Research (Google News) · 2026-08-12
- Analyst Maintains Buy Rating on BridgeBio Oncology Therapeutics, Reaffirming Unchanged $23 Price Target Ahead of Key 2026 KRAS Data Catalysts - TipRanks · KRAS Mutation Research (Google News) · 2026-08-12
- A dual assault on KRAS - Nature · KRAS Mutation Research (Google News) · 2026-08-12
What the reporting says
It shows up alongside Colorectal Cancer (94), G12d (57), Pancreatic Cancer (49), Pdac (18), Braf (17), Immunotherapy (17), ctDNA (15), Mapk (12).
Two steps out: AI (through Colorectal Cancer, 61 shared stories on the weaker link); Wang (through Colorectal Cancer, 55 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 53 shared stories on the weaker link); Zhang (through Colorectal Cancer, 49 shared stories on the weaker link).
Tracked since Mar 11, with coverage on 126 separate days — concentrated in Oncology and Pubmed Targeted.